RAB11 binding and LisH domain, coiled-coil and HEAT repeat containingGenealiases: HsT3308 · HsT885 · KIAA1468
Q-omics provides the consensus-scored RELCH profile across patient tissues and cancer cell-line models. RELCH expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RELCH is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, RELCH protein abundance shows 21,243 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LIHC, and GBM as cancer lineages where RELCH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RELCH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RELCH survival associations across molecular data types. RELCH RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RELCH RNA expression–survival associations across cancer types. High RELCH expression shows unfavorable associations in ACC, MESO, LIHC and UVM, but favorable associations in KIRC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RELCH RNA expression.
This table summarizes RELCH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RELCH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RELCH shows lower tumor expression in COAD, KICH and HNSC and higher tumor expression in LIHC, LUSC and CHOL. The LIHC box plot shows higher RELCH RNA expression in tumor versus normal tissue (log2 FC = +0.471, t-test p < 0.001).
This table shows molecular features associated with RELCH in patient tissues and cancer cell lines. In patient samples, RELCH shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RELCH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
